Related Experiment Video
Updated: Oct 2, 2026
Transcutaneous Microcirculatory Imaging in Preterm Neonates
Published on: December 31, 2015
Lifetime patient outcomes and healthcare utilization for Bronchopulmonary dysplasia (BPD) and extreme preterm
Sasha van Katwyk1,2, Sajit Augustine3,4, Bernard Thébaud1,5
1Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Insights
Bronchopulmonary dysplasia (BPD) significantly impacts premature infants, causing over $700,000 in lifetime costs and reduced life expectancy. Early intervention is crucial for mitigating BPD
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Health Economics
Background:
- Bronchopulmonary dysplasia (BPD) is a severe chronic lung disease primarily affecting premature infants.
- While short-term impacts are known, long-term outcomes and lifetime burden remain understudied.
- This research addresses the critical knowledge gap regarding the lifelong consequences of BPD.
Purpose of the Study:
- To estimate the lifetime clinical outcomes, quality of life, and healthcare costs associated with BPD.
- To quantify the cumulative incidence of major BPD complications.
- To differentiate outcomes based on BPD severity and gestational age.
Main Methods:
- Development of a microsimulation model to assess the lifetime burden of BPD.
- Validation of the model using Canadian healthcare data.
- Estimation of complication incidence across BPD severity and gestational age categories.
Main Results:
- Average lifetime healthcare costs for BPD patients exceed CAD$700,000.
- BPD patients experience reduced life expectancy and significant decreases in quality-adjusted life years.
- Outcomes vary substantially with BPD severity, indicating potential for therapeutic interventions.
Conclusions:
- This study provides a comprehensive lifetime burden estimate for BPD based on patient characteristics.
- The substantial early-life cost and lifelong quality of life impact highlight the need for increased investment in BPD prevention and mitigation.
- Significant therapeutic headroom exists for interventions targeting severe BPD.
Background:
Bronchopulmonary dysplasia (BPD) is among the most severe chronic lung diseases and predominantly affects premature infants. There is a general understanding of BPD's significant impact on the short-term outcomes however there is little evidence on long-term outcomes. Our study estimates the lifetime clinical outcomes, quality of life, and healthcare costs of BPD and associated complications.
Methods:
We developed a microsimulation model to estimate lifetime clinical and economic burden of BPD among extreme preterm infants (≤28 weeks gestational age at birth) and validated it against the best available Canadian data. We further estimate the cumulative incidence of major complications associated with BPD, differentiated by BPD severity and gestational age category.
Results:
We find, on average, patients with BPD and resulting complications will incur over CAD$700,000 in lifetime health systems costs. We also find the average life expectancy of BPD patients to be moderately less than that of the general population and significant reductions in quality-adjusted life year due to major complications. Healthcare utilization and quality of life measures vary dramatically according to BPD severity, suggesting significant therapeutic headroom for interventions that can prevent or mitigate the effects of BPD for patients.
Conclusions:
Our study adds a significant expansion of existing evidence by presenting the lifetime burden of BPD based on key patient characteristics. Given the extreme cost burden at the earliest stage of life and lifetime negative impact on quality of life, there is larger headroom for investment in prevention and mitigation of severe BPD than is currently available.
